Alkermes plc
General ticker "ALKS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.9B (TTM average)
Alkermes plc follows the US Stock Market performance with the rate: 47.1%.
Estimated limits based on current volatility of 2.9%: low 40.63$, high 43.09$
Factors to consider:
- Total employees count: 1800 as of 2024
- US accounted for 90.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Regulatory and compliance, Labor/talent shortage/retention, Pandemic risks, Litigation risks
- Current price 21.4% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [22.33$, 35.23$]
- 2026-12-31 to 2027-12-31 estimated range: [24.40$, 37.86$]
Financial Metrics affecting the ALKS estimates:
- Positive: with PPE of 19.1 at the end of fiscal year the price was neutral
- Positive: 7.54 < Operating profit margin, % of 17.21
- Positive: 6.59 < Operating cash flow per share per price, % of 11.20
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 6.36 > -0.60
- Negative: Industry earnings per price (median), % of -13.66 <= 0
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.86 > 6.06
- Negative: Inventory ratio change, % of 1.31 > 0.78
- Negative: negative Industry operating income (median)
Short-term ALKS quotes
Long-term ALKS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,663.40MM | $1,557.63MM | $1,475.90MM |
| Operating Expenses | $1,249.28MM | $1,137.00MM | $1,221.94MM |
| Operating Income | $414.12MM | $420.64MM | $253.96MM |
| Non-Operating Income | $7.40MM | $23.11MM | $37.49MM |
| Interest Expense | $23.03MM | $22.58MM | $12.28MM |
| R&D Expense | $270.81MM | $245.33MM | $323.96MM |
| Income(Loss) | $421.52MM | $443.75MM | $291.45MM |
| Taxes | $-97.64MM | $71.61MM | $49.79MM |
| Other Income(Loss) | $-163.40MM | $-5.07MM | $0.00MM |
| Net Income(Loss)* | $192.36MM | $362.00MM | $241.66MM |
| Stockholders Equity | $1,202.69MM | $1,464.98MM | $1,819.30MM |
| Inventory | $186.41MM | $182.89MM | $196.62MM |
| Assets | $2,136.22MM | $2,055.57MM | $2,486.99MM |
| Operating Cash Flow | $401.35MM | $439.12MM | $520.75MM |
| Capital expenditure | $48.05MM | $33.48MM | $40.42MM |
| Investing Cash Flow | $53.36MM | $-111.31MM | $295.50MM |
| Financing Cash Flow | $-289.71MM | $-494.14MM | $12.38MM |
| Earnings Per Share** | $1.16 | $2.19 | $1.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.